O	0	7	Quality
O	8	10	of
O	11	15	life
O	16	18	in
O	19	24	newly
O	25	34	diagnosed
B-Disease	35	43	glaucoma
O	44	52	patients
O	53	54	:
O	55	58	The
O	59	72	Collaborative
O	73	80	Initial
B-Disease	81	89	Glaucoma
O	90	99	Treatment
O	100	105	Study
O	105	106	.

O	108	111	The
O	112	125	Collaborative
O	126	133	Initial
B-Disease	134	142	Glaucoma
O	143	152	Treatment
O	153	158	Study
O	159	160	(
O	160	165	CIGTS
O	165	166	)
O	167	170	was
O	171	179	designed
O	180	182	to
O	183	192	determine
O	193	200	whether
O	201	209	patients
O	210	214	with
O	215	220	newly
O	221	230	diagnosed
B-Disease	231	235	open
I-Disease	235	236	-
I-Disease	236	241	angle
I-Disease	242	250	glaucoma
O	251	254	are
O	255	261	better
O	262	269	treated
O	270	279	initially
O	280	282	by
O	283	291	medicine
O	292	294	or
O	295	304	immediate
O	305	314	filtering
O	315	322	surgery
O	322	323	.

O	324	328	This
O	329	334	paper
O	335	344	describes
O	345	348	the
O	349	356	quality
O	356	357	-
O	357	359	of
O	359	360	-
O	360	364	life
O	365	366	(
O	366	369	QOL
O	369	370	)
O	371	382	measurement
O	383	391	approach
O	391	392	,
O	393	404	instruments
O	405	413	included
O	413	414	,
O	415	418	and
O	419	422	the
O	423	428	CIGTS
O	429	441	participants
O	441	442	'
O	443	446	QOL
O	447	455	findings
O	456	458	at
O	459	462	the
O	463	467	time
O	468	470	of
O	471	480	diagnosis
O	480	481	.

O	482	490	Baseline
O	491	498	results
O	499	503	from
O	504	505	a
O	506	516	randomized
O	516	517	,
O	518	528	controlled
O	529	537	clinical
O	538	543	trial
O	543	544	.

O	545	548	Six
O	549	556	hundred
O	557	562	seven
O	563	571	patients
O	572	576	from
O	577	579	14
O	580	588	clinical
O	589	596	centers
O	597	601	were
O	602	610	enrolled
O	610	611	.

O	612	620	Patients
O	621	631	randomized
O	632	634	to
O	635	642	initial
O	643	653	medication
O	654	662	received
O	663	664	a
O	665	672	stepped
O	673	680	medical
O	681	688	regimen
O	689	690	(
O	690	691	n
O	692	693	=
O	694	697	307
O	697	698	)
O	698	699	.

O	700	705	Those
O	706	716	randomized
O	717	719	to
O	720	727	initial
O	728	735	surgery
O	736	745	underwent
O	746	747	a
O	748	762	trabeculectomy
O	763	764	(
O	764	765	n
O	766	767	=
O	768	771	300
O	771	772	)
O	772	773	.

O	774	777	The
O	778	786	baseline
O	787	796	interview
O	797	800	was
O	801	810	conducted
O	811	817	before
O	818	827	treatment
O	828	838	initiation
O	838	839	.

O	840	843	All
O	844	852	baseline
O	853	856	and
O	857	870	posttreatment
O	871	874	QOL
O	875	886	assessments
O	887	891	were
O	892	901	conducted
O	902	904	by
O	905	914	telephone
O	915	919	from
O	920	921	a
O	922	933	centralized
O	934	946	interviewing
O	947	953	center
O	953	954	.

O	955	958	The
O	959	966	primary
O	967	974	outcome
O	975	982	measure
O	983	992	described
O	993	995	in
O	996	1000	this
O	1001	1006	paper
O	1007	1010	was
O	1011	1014	QOL
O	1014	1015	.

O	1016	1019	The
B-Diagnostic_tool	1020	1023	QOL
I-Diagnostic_tool	1024	1034	instrument
O	1035	1037	is
O	1038	1054	multidimensional
O	1055	1058	and
O	1059	1071	incorporates
O	1072	1076	both
O	1077	1084	disease
O	1084	1085	-
O	1085	1093	specific
O	1094	1097	and
O	1098	1105	generic
O	1106	1114	measures
O	1114	1115	,
O	1116	1125	including
O	1126	1129	the
B-Diagnostic_tool	1130	1136	Visual
I-Diagnostic_tool	1137	1147	Activities
I-Diagnostic_tool	1148	1161	Questionnaire
O	1161	1162	,
O	1163	1171	Sickness
O	1172	1178	Impact
O	1179	1186	Profile
O	1186	1187	,
O	1188	1191	and
O	1192	1193	a
O	1194	1201	Symptom
O	1202	1205	and
O	1206	1212	Health
O	1213	1220	Problem
O	1221	1230	CHECKLIST
O	1230	1231	:
O	1232	1235	The
O	1236	1248	correlations
O	1249	1256	between
O	1257	1260	QOL
O	1261	1269	measures
O	1270	1273	and
O	1274	1282	clinical
O	1283	1291	outcomes
O	1292	1296	were
O	1297	1299	in
O	1300	1303	the
O	1304	1312	expected
O	1313	1322	direction
O	1322	1323	,
O	1324	1327	but
O	1328	1338	relatively
O	1339	1343	weak
O	1343	1344	.

O	1345	1347	At
O	1348	1355	initial
O	1356	1365	diagnosis
O	1365	1366	,
O	1367	1377	difficulty
O	1378	1382	with
O	1383	1389	bright
O	1390	1396	lights
O	1397	1400	and
O	1401	1405	with
O	1406	1411	light
O	1412	1415	and
O	1416	1420	dark
O	1421	1431	adaptation
O	1432	1436	were
O	1437	1440	the
O	1441	1445	most
O	1446	1456	frequently
O	1457	1465	reported
O	1466	1474	symptoms
O	1475	1482	related
O	1483	1485	to
B-Characteristic	1486	1492	visual
I-Characteristic	1493	1501	function
O	1501	1502	,
O	1503	1510	whereas
B-Symptom	1511	1517	visual
I-Symptom	1518	1528	distortion
O	1529	1532	was
O	1533	1536	the
O	1537	1541	most
O	1542	1552	bothersome
O	1552	1553	.

O	1554	1567	Approximately
O	1568	1572	half
O	1573	1575	of
O	1576	1579	the
O	1580	1588	patients
O	1589	1597	reported
O	1598	1600	at
O	1601	1606	least
O	1607	1611	some
O	1612	1617	worry
O	1618	1620	or
O	1621	1628	concern
O	1629	1634	about
O	1635	1638	the
O	1639	1650	possibility
O	1651	1653	of
B-Symptom	1654	1663	blindness
O	1663	1664	.

O	1665	1671	Within
O	1672	1675	the
B-Diagnostic_tool	1676	1682	Visual
I-Diagnostic_tool	1683	1693	Activities
I-Diagnostic_tool	1694	1707	Questionnaire
O	1707	1708	,
O	1709	1715	higher
O	1716	1722	scores
O	1723	1725	on
O	1726	1729	the
B-Diagnostic_tool	1730	1740	Peripheral
I-Diagnostic_tool	1741	1747	Vision
I-Diagnostic_tool	1748	1756	subscale
O	1757	1761	were
O	1762	1772	associated
O	1773	1777	with
O	1778	1782	more
B-Symptom	1783	1788	field
I-Symptom	1789	1793	loss
O	1794	1795	(
O	1795	1796	P
O	1798	1799	<
O	1801	1802	0
O	1802	1803	.
O	1803	1805	01
O	1805	1806	)
O	1806	1807	.

O	1808	1810	In
O	1811	1821	regression
O	1822	1830	analyses
O	1831	1842	controlling
O	1843	1846	for
B-Characteristic	1847	1864	sociodemographics
O	1865	1868	and
B-Symptom	1869	1878	nonocular
I-Symptom	1879	1892	comorbidities
O	1892	1893	,
O	1894	1903	increased
B-Symptom	1904	1910	visual
I-Symptom	1911	1916	field
I-Symptom	1917	1921	loss
O	1922	1925	was
O	1926	1939	significantly
O	1940	1950	associated
O	1951	1955	with
O	1956	1962	higher
O	1963	1974	dysfunction
O	1975	1980	among
O	1981	1985	five
O	1986	1993	disease
O	1993	1994	-
O	1994	2002	specific
O	2003	2006	QOL
O	2007	2015	measures
O	2016	2017	(
O	2017	2018	P
O	2020	2021	<
O	2023	2024	0
O	2024	2025	.
O	2025	2027	05
O	2027	2028	)
O	2028	2029	.

O	2030	2035	Newly
O	2036	2045	diagnosed
B-Disease	2046	2054	glaucoma
O	2055	2063	patients
O	2064	2072	reported
O	2073	2085	experiencing
O	2086	2090	some
B-Symptom	2091	2097	visual
I-Symptom	2098	2106	function
I-Symptom	2107	2115	symptoms
O	2116	2118	at
O	2119	2122	the
O	2123	2127	time
O	2128	2130	of
O	2131	2140	diagnosis
O	2141	2145	that
O	2146	2151	would
O	2152	2155	not
O	2156	2158	be
O	2159	2170	intuitively
O	2171	2179	expected
O	2180	2185	based
O	2186	2188	on
O	2189	2197	clinical
O	2198	2205	testing
O	2205	2206	.

O	2207	2211	Some
O	2212	2222	discussion
O	2223	2228	about
O	2229	2232	the
O	2233	2244	association
O	2245	2252	between
O	2253	2261	clinical
O	2262	2274	presentation
O	2275	2278	and
O	2279	2284	worry
O	2285	2290	about
B-Symptom	2291	2300	blindness
O	2301	2304	may
O	2305	2311	reduce
O	2312	2323	unnecessary
O	2324	2331	concern
O	2331	2332	.

O	2333	2338	These
O	2339	2346	results
O	2347	2354	provide
O	2355	2358	the
O	2359	2364	basis
O	2365	2368	for
O	2369	2373	long
O	2373	2374	-
O	2374	2378	term
O	2379	2390	comparisons
O	2391	2393	of
O	2394	2397	the
O	2398	2401	QOL
O	2402	2409	effects
O	2410	2412	of
O	2413	2420	initial
O	2421	2428	medical
O	2429	2432	and
O	2433	2441	surgical
O	2442	2451	treatment
O	2452	2455	for
B-Disease	2456	2460	open
I-Disease	2460	2461	-
I-Disease	2461	2466	angle
I-Disease	2467	2475	glaucoma
O	2475	2476	.
